A lawsuit filed in San Francisco alleges that Oura’s sleep ring uses artificial intelligence guesses rather than direct measurement to determine sleep stages, and that its advertised 95% accuracy compared to clinical sleep labs is unsupported. Oura maintains confidence in its scientific claims amid growing scrutiny.
- Lawsuit contests Oura’s 95% sleep stage accuracy claim.
- AI-based sleep staging challenged against clinical polysomnography standards.
- Case affects product claims in both US and European markets.
What happened
A proposed class action lawsuit was filed in the Northern District of California against Oura Inc. and its Finnish parent company Oura Health Oy. The suit alleges that the company’s flagship product, the Oura ring, does not support its advertised claim of achieving 95% accuracy in sleep stage tracking compared to clinical sleep tests. Plaintiffs argue the ring's data is not a direct measurement but generated by AI-based guesses that at best hit accuracy equivalent to a coin flip.
The legal complaint references a clinical study involving 45 patients, which found that the Oura ring’s classification of sleep stages had an overall accuracy of just over 53%. The study also noted a significant overestimation of REM sleep duration. The lawsuit brings multiple charges including fraud, false advertising, and violations of California’s Unfair Competition Law.
Why it matters
If substantiated, this case could expose the limitations of wearables in accurately replicating clinical diagnostic tools such as polysomnography, which uses brain and eye activity measurements. The litigation targets the core marketing claim driving consumer demand and investor confidence in Oura’s products and technology.
The case is particularly sensitive as Oura recently confidentially filed for a US IPO with a valuation of $11 billion, making it the most valuable European consumer health hardware startup. Additionally, similar marketing claims are made in Europe where consumer protection laws prohibit misleading advertising, potentially exposing Oura to parallel regulatory scrutiny amid evolving collective redress mechanisms.
What to watch next
Legal developments in this case will be closely monitored for their impact on sleep tracking technology, wearable health device marketing, and investor sentiment toward health tech companies going public. How courts interpret the accuracy claim and the robustness of the supporting science could set precedents for future consumer tech advertising disputes.
European consumer organizations may also leverage the new Representative Actions Directive enabling collective actions on unfair commercial practices to challenge Oura’s claims. Observers should watch for any filings or regulatory actions in the EU that echo the US litigation, which would signal heightened scrutiny on accuracy claims in the wearable health device sector globally.